Human TSLP OneStep ELISA Kit

Human Thymic Stromal Lymphopoietin (TSLP) is a short-chain four-α-helix bundle type I cytokine that exists in two functionally distinct isoforms: the pro-inflammatory long-form (lfTSLP) and the antimicrobial short-form (sfTSLP). As an epithelial-derived alarmin, lfTSLP sits at the top of the type 2 inflammatory cascade, exerting its effects by forming a high-affinity ternary complex with its specific receptor TSLPR and the shared IL-7Rα chain, which subsequently activates downstream JAK-STAT pathways to drive both innate and adaptive Th2-mediated immune responses. Structurally, this interaction involves a receptor-binding mechanism where TSLP first engages TSLPR, followed by the recruitment of IL-7Rα. Due to its pivotal role as a master regulator of allergic inflammation, TSLP has emerged as a crucial therapeutic target, highlighted by the clinical approval of anti-TSLP monoclonal antibodies like Tezepelumab for asthma, and the ongoing development of next-generation biologics such as bispecific antibodies and biparatopic nanobodies designed to block this signaling pathway more potently.